Concepts (128)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 20 | 2024 | 4946 | 0.830 |
Why?
|
| Sarcoma, Kaposi | 4 | 2023 | 52 | 0.710 |
Why?
|
| Tuberculosis | 6 | 2024 | 530 | 0.670 |
Why?
|
| Anti-HIV Agents | 10 | 2021 | 1275 | 0.640 |
Why?
|
| Isoniazid | 5 | 2024 | 110 | 0.620 |
Why?
|
| Anti-Retroviral Agents | 7 | 2022 | 542 | 0.600 |
Why?
|
| Antiretroviral Therapy, Highly Active | 7 | 2020 | 468 | 0.590 |
Why?
|
| AIDS-Related Opportunistic Infections | 4 | 2020 | 194 | 0.540 |
Why?
|
| Micronutrients | 3 | 2018 | 11 | 0.430 |
Why?
|
| Rifampin | 4 | 2022 | 189 | 0.410 |
Why?
|
| C-Reactive Protein | 4 | 2015 | 96 | 0.400 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2020 | 9 | 0.380 |
Why?
|
| Inflammation | 4 | 2023 | 103 | 0.360 |
Why?
|
| Biomarkers | 3 | 2023 | 322 | 0.320 |
Why?
|
| Adult | 18 | 2021 | 5664 | 0.320 |
Why?
|
| Etoposide | 4 | 2023 | 4 | 0.310 |
Why?
|
| Male | 18 | 2021 | 6489 | 0.300 |
Why?
|
| Humans | 22 | 2024 | 14077 | 0.270 |
Why?
|
| Nevirapine | 3 | 2022 | 146 | 0.270 |
Why?
|
| Female | 18 | 2024 | 8751 | 0.270 |
Why?
|
| Alkynes | 3 | 2022 | 113 | 0.260 |
Why?
|
| Cyclopropanes | 3 | 2022 | 119 | 0.260 |
Why?
|
| Antitubercular Agents | 4 | 2024 | 299 | 0.260 |
Why?
|
| Malnutrition | 2 | 2017 | 53 | 0.260 |
Why?
|
| Benzoxazines | 3 | 2022 | 119 | 0.260 |
Why?
|
| Abortion, Spontaneous | 1 | 2024 | 11 | 0.230 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 2 | 2020 | 33 | 0.220 |
Why?
|
| Premature Birth | 1 | 2024 | 76 | 0.210 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2023 | 186 | 0.200 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2020 | 2 | 0.180 |
Why?
|
| Bleomycin | 1 | 2020 | 2 | 0.180 |
Why?
|
| Vincristine | 1 | 2020 | 5 | 0.180 |
Why?
|
| Coinfection | 2 | 2020 | 268 | 0.180 |
Why?
|
| Viral Load | 3 | 2020 | 808 | 0.170 |
Why?
|
| CD4 Lymphocyte Count | 5 | 2020 | 654 | 0.170 |
Why?
|
| Latent Tuberculosis | 1 | 2019 | 45 | 0.160 |
Why?
|
| Treatment Outcome | 5 | 2020 | 867 | 0.160 |
Why?
|
| Developing Countries | 3 | 2020 | 385 | 0.160 |
Why?
|
| Selenium | 2 | 2015 | 3 | 0.150 |
Why?
|
| Health Resources | 2 | 2018 | 65 | 0.150 |
Why?
|
| Vitamin A Deficiency | 1 | 2017 | 5 | 0.150 |
Why?
|
| Vitamin D | 2 | 2015 | 39 | 0.150 |
Why?
|
| Secondary Prevention | 1 | 2017 | 20 | 0.140 |
Why?
|
| Vitamin D Deficiency | 1 | 2017 | 27 | 0.140 |
Why?
|
| Inflammation Mediators | 1 | 2016 | 22 | 0.140 |
Why?
|
| Weight Loss | 1 | 2016 | 12 | 0.130 |
Why?
|
| Sex Factors | 1 | 2016 | 224 | 0.130 |
Why?
|
| Body Weight | 1 | 2016 | 110 | 0.130 |
Why?
|
| Young Adult | 5 | 2021 | 2357 | 0.130 |
Why?
|
| Weight Gain | 1 | 2016 | 73 | 0.130 |
Why?
|
| Chemokine CXCL10 | 1 | 2015 | 3 | 0.130 |
Why?
|
| Lipopolysaccharides | 1 | 2015 | 37 | 0.120 |
Why?
|
| Anemia | 1 | 2015 | 41 | 0.120 |
Why?
|
| Drug Therapy, Combination | 3 | 2020 | 271 | 0.110 |
Why?
|
| Prospective Studies | 4 | 2017 | 1131 | 0.100 |
Why?
|
| Treatment Failure | 3 | 2018 | 175 | 0.100 |
Why?
|
| Middle Aged | 4 | 2021 | 3425 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2018 | 464 | 0.090 |
Why?
|
| South America | 2 | 2020 | 26 | 0.090 |
Why?
|
| HIV-1 | 1 | 2018 | 1239 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2017 | 939 | 0.080 |
Why?
|
| Africa South of the Sahara | 2 | 2020 | 328 | 0.080 |
Why?
|
| Disease Progression | 2 | 2020 | 154 | 0.070 |
Why?
|
| Africa | 2 | 2020 | 360 | 0.070 |
Why?
|
| Risk Factors | 3 | 2015 | 1431 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 171 | 0.060 |
Why?
|
| Pregnancy Trimester, First | 1 | 2024 | 10 | 0.060 |
Why?
|
| Logistic Models | 2 | 2015 | 252 | 0.060 |
Why?
|
| Chemoradiotherapy | 1 | 2023 | 3 | 0.060 |
Why?
|
| Interleukin-10 | 1 | 2023 | 9 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2023 | 4 | 0.060 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2023 | 11 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 14 | 0.060 |
Why?
|
| Ligands | 1 | 2023 | 33 | 0.060 |
Why?
|
| Adolescent | 2 | 2021 | 2858 | 0.060 |
Why?
|
| Aged | 2 | 2021 | 1650 | 0.060 |
Why?
|
| Pregnancy Outcome | 1 | 2024 | 112 | 0.060 |
Why?
|
| Incidence | 2 | 2015 | 655 | 0.050 |
Why?
|
| Prevalence | 2 | 2017 | 1149 | 0.050 |
Why?
|
| HIV | 1 | 2024 | 380 | 0.050 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2021 | 6 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2021 | 20 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2021 | 27 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2020 | 5 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 32 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2024 | 1410 | 0.040 |
Why?
|
| Oxazines | 1 | 2020 | 71 | 0.040 |
Why?
|
| Piperazines | 1 | 2020 | 73 | 0.040 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2020 | 76 | 0.040 |
Why?
|
| Pyridones | 1 | 2020 | 87 | 0.040 |
Why?
|
| Trace Elements | 1 | 2018 | 3 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 153 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2020 | 303 | 0.040 |
Why?
|
| Biopsy | 1 | 2018 | 37 | 0.040 |
Why?
|
| Skin | 1 | 2018 | 38 | 0.040 |
Why?
|
| Pregnancy | 1 | 2024 | 1815 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2018 | 113 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 163 | 0.040 |
Why?
|
| Infant | 1 | 2024 | 2145 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2019 | 137 | 0.040 |
Why?
|
| Asia | 1 | 2017 | 70 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 145 | 0.030 |
Why?
|
| Haiti | 1 | 2016 | 1 | 0.030 |
Why?
|
| Peru | 1 | 2016 | 8 | 0.030 |
Why?
|
| Thailand | 1 | 2016 | 24 | 0.030 |
Why?
|
| Brazil | 1 | 2016 | 43 | 0.030 |
Why?
|
| India | 1 | 2016 | 60 | 0.030 |
Why?
|
| Malawi | 1 | 2016 | 86 | 0.030 |
Why?
|
| United States | 1 | 2016 | 129 | 0.030 |
Why?
|
| Zimbabwe | 1 | 2016 | 115 | 0.030 |
Why?
|
| Carotenoids | 1 | 2015 | 2 | 0.030 |
Why?
|
| Vitamin A | 1 | 2015 | 10 | 0.030 |
Why?
|
| Vitamin E | 1 | 2015 | 9 | 0.030 |
Why?
|
| Atazanavir Sulfate | 1 | 2014 | 10 | 0.030 |
Why?
|
| Pyridines | 1 | 2014 | 10 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 87 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2014 | 12 | 0.030 |
Why?
|
| Didanosine | 1 | 2014 | 11 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2014 | 16 | 0.030 |
Why?
|
| Global Health | 1 | 2015 | 183 | 0.030 |
Why?
|
| Zidovudine | 1 | 2014 | 59 | 0.030 |
Why?
|
| Emtricitabine | 1 | 2014 | 74 | 0.030 |
Why?
|
| Lamivudine | 1 | 2014 | 86 | 0.030 |
Why?
|
| World Health Organization | 1 | 2014 | 134 | 0.030 |
Why?
|
| African Americans | 1 | 2014 | 47 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2014 | 131 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2014 | 312 | 0.030 |
Why?
|
| South Africa | 1 | 2016 | 7312 | 0.010 |
Why?
|